Ondine Biomedical Inc.

Transaction in Own Shares • Dec 30, 2022

National Storage Mechanism | Additional information

RNS Number : 3791L

Ondine Biomedical Inc.

30 December 2022

30/12/2022

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Appointment of Nominated Adviser

Ondine Biomedical Inc. (AIM: OBI), Canadian life sciences company developing photodisinfection-based solutions to healthcare-associated infections, has appointed Singer Capital Markets as its Nominated Adviser with immediate effect. Singer Capital Markets and RBC Capital Markets both continue to act as joint brokers to the Company.

Ondine Biomedical Inc.
Angelika Vance, Corporate Communications	+001 (1) 604 838 2702
Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell, Asha Chotai, Sam Butcher	+44 (0)20 7496 3000
RBC Capital Markets (Joint Broker)
Rupert Walford, Kathryn Deegan	+44 (0) 20 7653 4000
Vane Percy & Roberts (Media Contact)
Simon Vane Percy, Amanda Bernard	+44 (0) 77 1000 5910

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPEAAAEDAPAFFA